Insider Buying: Lyell Immunopharma, Inc. (NASDAQ:LYEL) CFO Buys 200,000 Shares of Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CFO Charles W. Newton bought 200,000 shares of Lyell Immunopharma stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $0.56 per share, for a total transaction of $112,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 200,000 shares in the company, valued at $112,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Lyell Immunopharma Price Performance

Shares of LYEL traded down $0.03 on Tuesday, hitting $0.48. The company’s stock had a trading volume of 1,199,720 shares, compared to its average volume of 1,043,773. The company has a market capitalization of $142.80 million, a PE ratio of -0.61 and a beta of -0.41. Lyell Immunopharma, Inc. has a fifty-two week low of $0.48 and a fifty-two week high of $3.15. The company has a 50 day moving average price of $0.62 and a 200 day moving average price of $0.90.

Lyell Immunopharma (NASDAQ:LYEL) last announced its earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The business had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. On average, equities analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Barclays PLC lifted its holdings in Lyell Immunopharma by 7.4% during the 4th quarter. Barclays PLC now owns 258,380 shares of the company’s stock worth $165,000 after buying an additional 17,765 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Lyell Immunopharma by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 94,320 shares of the company’s stock worth $60,000 after buying an additional 20,542 shares in the last quarter. Centiva Capital LP acquired a new position in Lyell Immunopharma during the 3rd quarter worth $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Lyell Immunopharma by 13.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company’s stock worth $197,000 after buying an additional 36,555 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in Lyell Immunopharma during the 3rd quarter worth $52,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating and issued a $1.00 target price on shares of Lyell Immunopharma in a report on Thursday, March 13th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.